FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical firm with a market capitalization of $119.87 billion, announced today a 2.6% increase in its quarterly cash dividend.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported in Q4 CY2024, with sales up 6.4% year on year to $7.57 ...

Gilead Sciences Inc. (GILD) on Tuesday reported fourth-quarter earnings of $1.78 billion. The Foster City, California-based company said it ...

This was the stock's second consecutive day of losses.

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on ...

$2,440,000 of GILEAD SCIENCES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "International trade and protection ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January 16th.

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...